BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. Visc Med. 2019;35:161-170. [PMID: 31367613 DOI: 10.1159/000500963] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Khalsa JH, Mathur P. Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. Viruses 2021;13:1363. [PMID: 34372569 DOI: 10.3390/v13071363] [Reference Citation Analysis]
3 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
4 Burchill MA, Salomon MP, Golden-Mason L, Wieland A, Maretti-Mira AC, Gale M Jr, Rosen HR. Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes. PLoS Pathog 2021;17:e1009799. [PMID: 34370798 DOI: 10.1371/journal.ppat.1009799] [Reference Citation Analysis]
5 Schlevogt B, Boeker KHW, Mauss S, Klinker H, Heyne R, Link R, Simon KG, Sarrazin C, Serfert Y, Manns MP, Wedemeyer H. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R). Biomedicines 2021;9:1495. [PMID: 34680612 DOI: 10.3390/biomedicines9101495] [Reference Citation Analysis]
6 Teaima MH, Al-Nuseirat A, Abouhussein D, Badary OA, El-Nabarawi MA. Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt-case study. J Pharm Policy Pract 2021;14:106. [PMID: 34915937 DOI: 10.1186/s40545-021-00389-6] [Reference Citation Analysis]
7 Andreoni M, Di Perri G, Persico M, Marcellusi A, Ethgen O, Sanchez Gonzalez Y, Bondin M, Zhang Z, De Michina A, Merolla RCD, Craxì A. Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy. Infect Dis Ther 2021;10:763-74. [PMID: 33655410 DOI: 10.1007/s40121-021-00410-0] [Reference Citation Analysis]
8 Tomiyasu H, Nakajima S, Kaku Y, Hirata M, Kataoka T, Nomura T, Kabashima K. A possible case of maculopapular eruption associated with glecaprevir/pibrentasvir treatment for chronic hepatitis C virus infection. J Cutan Immunol Allergy 2021;4:92-4. [DOI: 10.1002/cia2.12166] [Reference Citation Analysis]
9 Jeong S, Lee YS, Kim K, Yoon JS, Kim S, Ha J, Kang I, Choe W. 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation. Int J Mol Sci 2021;22:6499. [PMID: 34204438 DOI: 10.3390/ijms22126499] [Reference Citation Analysis]
10 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kobayashi T, Yasuno T, Takahashi K, Nakamura S, Mashino T, Ohe T. Novel pyridinium-type fullerene derivatives as multitargeting inhibitors of HIV-1 reverse transcriptase, HIV-1 protease, and HCV NS5B polymerase. Bioorg Med Chem Lett 2021;49:128267. [PMID: 34271071 DOI: 10.1016/j.bmcl.2021.128267] [Reference Citation Analysis]
12 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Schwerk J, Negash A, Savan R, Gale M Jr. Innate Immunity in Hepatitis C Virus Infection. Cold Spring Harb Perspect Med 2021;11:a036988. [PMID: 32341066 DOI: 10.1101/cshperspect.a036988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020; 12(5): 220-229 [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Reference Citation Analysis]
15 Mishra S, Pandey A, Manvati S. Coumarin: An emerging antiviral agent. Heliyon 2020;6:e03217. [PMID: 32042967 DOI: 10.1016/j.heliyon.2020.e03217] [Cited by in Crossref: 45] [Cited by in F6Publishing: 27] [Article Influence: 22.5] [Reference Citation Analysis]
16 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
17 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
18 Cornberg M, Manns MP. The curing regimens of HCV: A SWOT analysis. Antivir Ther 2022;27:13596535211072672. [PMID: 35491553 DOI: 10.1177/13596535211072672] [Reference Citation Analysis]
19 Mekonnen ZA, Masavuli MG, Yu W, Gummow J, Whelan DM, Al-Delfi Z, Torresi J, Gowans EJ, Grubor-Bauk B. Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3. Front Microbiol 2020;11:559105. [PMID: 33343515 DOI: 10.3389/fmicb.2020.559105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Berkan-Kawińska A, Piekarska A, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Berak H, Horban A, Zarębska-Michaluk D, Pabjan P, Buczyńska I, Pazgan-Simon M, Dybowska D, Halota W, Pawłowska M, Klapaczyński J, Mazur W, Czauż-Andrzejuk A, Socha Ł, Laurans Ł, Garlicki A, Sitko M, Jaroszewicz J, Citko J, Dobracka B, Krygier R, Białkowska-Warzecha J, Tronina O, Belica-Wdowik T, Baka-Ćwierz B, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver Int 2021;41:1789-801. [PMID: 33655628 DOI: 10.1111/liv.14858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Citarella A, Gentile D, Rescifina A, Piperno A, Mognetti B, Gribaudo G, Sciortino MT, Holzer W, Pace V, Micale N. Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses. Int J Mol Sci 2021;22:1398. [PMID: 33573283 DOI: 10.3390/ijms22031398] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
23 Lee S, Mailar K, Kim MI, Park M, Kim J, Min DH, Heo TH, Bae SK, Choi W, Lee C. Plant-Derived Purification, Chemical Synthesis, and In Vitro/In Vivo Evaluation of a Resveratrol Dimer, Viniferin, as an HCV Replication Inhibitor. Viruses 2019;11:E890. [PMID: 31547617 DOI: 10.3390/v11100890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Sarrazin C, Boesecke C, Golsabahi-Broclawski S, Moog G, Negro F, Silaidos C, Patel P, Lohmann K, Spinner CD, Walcher S, Wedemeyer H, Wörns MA. Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. Health Sci Rep 2021;4:e290. [PMID: 34136654 DOI: 10.1002/hsr2.290] [Reference Citation Analysis]
25 Nishiguchi J, McNamara A, Surlyn CS, Eagen KV, Feeney L, Lian V, Smith DE. Efficacy of an eConsult service to cure hepatitis C in primary care. J Viral Hepat 2022;29:21-5. [PMID: 34586710 DOI: 10.1111/jvh.13616] [Reference Citation Analysis]
26 Lu Y, Yang X, Zhang L. Domain I of hepatitis C virus NS5A associates with ACBD3 in a genotype-dependent manner. Microbiol Immunol 2020;64:574-7. [PMID: 32108375 DOI: 10.1111/1348-0421.12784] [Reference Citation Analysis]
27 Parmar P, Shafran SD, Borgia SM, Doucette K, Cooper CL. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. JGH Open 2021;5:253-7. [PMID: 33553664 DOI: 10.1002/jgh3.12480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]